MedTrace Logo

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

NCT04218409 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-01-14

No results posted yet for this study

Summary

Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.

Conditions

Interventions

DRUG

OxyCODONE 5 mg Oral Tablet

Oral oxycodone 5 mg orally

DRUG

Oxytocin nasal spray

Intranasal oxytocin administration (48 IU)

OTHER

Placebo Oxycodone

Oxycodone 0 mg orally

OTHER

Placebo oxytocin

Intranasal placebo administration

DRUG

OxyCODONE 2.5 mg Oral Tablet

Oral oxycodone 2.5 mg orally

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Meredith Berry, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218409 on ClinicalTrials.gov